Home > Result Summaries: Compounds > otelixizumab > Result Summary for 115495

Result Summary for 115495

Result Summary

Protocol ID:	115495
Clinical Study ID:	OTX115495
Official Title:	Durable-Response Therapy Evaluation ForEarly or New-Onset Type 1 Diabetes - DEFEND
Phase:	phase 3
Study Indications or Diseases:	Diabetes Mellitus, Type 1
Generic Name:	otelixizumab
Trade/Product Name:	otelixizumab
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005 Jun 23;352(25):2598-608. You S, Candon S, Kuhn C, Bach JF, Chatenoud L. CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes. Adv Immunol. 2008;100:13-37. Review. No abstract available.